Loading
  • Cortisol Modulation
  • Stories
  • Careers
  • Contact
  • Home
  • About
    • Our Team
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Search
  • Menu Menu
  • Home
  • About
    • Teams
  • Products
    • Medical Information Request
  • Science
    • Pipeline and Clinical Trials
    • Cortisol Modulation
    • Therapeutic Areas
    • Publications
    • Investigator Initiated Studies
  • Resources
    • Grants
    • Compassionate use
    • State Required Notice
  • Stories
  • Careers
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
    • SEC Filings
  • Privacy Notice
  • Terms of Use
  • Site Map

Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.

December 2, 2019

Belanoff et al. • 2010 • Diabetes Obes Metab. 2010;12(6):545-7.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2019-12-02 00:00:002019-12-02 00:00:00Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.

Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis

November 10, 2019

Elhassan et al • 2019 • Ann Intern Med.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2019-11-10 00:00:002024-03-14 21:58:17Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-analysis

A mixed glucocorticoid/mineralocorticoid selective modulator with dominant antagonism in the male rat brain.

October 25, 2018

Atucha et al. • 2015 • Endocrinology. 2015;156(11):4105-4114.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-10-25 00:00:002024-03-12 00:37:53A mixed glucocorticoid/mineralocorticoid selective modulator with dominant antagonism in the male rat brain.

Identification of the clinical candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): a selective Glucocorticoid Receptor (GR) antagonist.

October 25, 2018

Hunt et al. • 2017 • J Med Chem. 2017;60(8):3405-3421.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-10-25 00:00:002018-10-25 00:00:00Identification of the clinical candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): a selective Glucocorticoid Receptor (GR) antagonist.

1H-pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoidreceptor antagonists with high functional activity.

October 25, 2018

Clark et al. • 2008 • Bioorg Med Chem Lett. 2008;18(4):1312-7.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-10-25 00:00:002018-10-25 00:00:001H-pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoidreceptor antagonists with high functional activity.

Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study.

October 25, 2018

Hunt et al. • 2017 • Clin Pharmacol Drug Dev. 2017 Oct 2. doi: 10.1002/cpdd.389.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-10-25 00:00:002018-10-25 00:00:00Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double-blind, randomized, placebo-controlled phase 1 clinical study.

FKBP5 mRNA expression is a biomarker for GR antagonism.

October 25, 2018

Bali et al. • 2016 • J Clin Endocrinol Metab. 2016;101(11):4305-4312.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-10-25 00:00:002018-10-25 00:00:00FKBP5 mRNA expression is a biomarker for GR antagonism.

Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth.

October 18, 2018

Kach et al. • 2017 • Mol Cancer Ther. 2017;16(8):1680-1692.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-10-18 00:00:002018-10-18 00:00:00Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth.

Selective glucocorticoid receptor antagonist CORT125281 activates brown adipose tissue and alters lipid distribution in male mice.

September 19, 2018

Kroon et al. • 2017 • Endocrinology. 2017 Sep 18. doi:10.1210/en.2017-00512.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-19 00:00:002018-09-19 00:00:00Selective glucocorticoid receptor antagonist CORT125281 activates brown adipose tissue and alters lipid distribution in male mice.

A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.

September 19, 2018

Mammi et al. • 2016 • Int J Obes (Lond). 2016;40(6):964-72.

Read more
https://corcept.com/wp-content/uploads/COR-logo.svg 0 0 jeremiah@devisedesigns.com https://corcept.com/wp-content/uploads/COR-logo.svg jeremiah@devisedesigns.com2018-09-19 00:00:002018-09-19 00:00:00A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.
Page 7 of 13«‹56789›»

Categories

  • Endocrinology
  • Hypercortisolism (Cushing syndrome)
  • Metabolism
  • Neurology
  • Oncology
  • Other
  • Uncategorized

© 2024 Corcept Therapeutics, Incorporated

Privacy Notice | Terms of Use | Site Map | Your Privacy Choices | LinkedIn | Youtube

Privacy Notice

Terms of Use

Site Map

Your Privacy Choices

LinkedIn

Youtube

Scroll to top